Literature DB >> 24813328

Insights into the activation and inhibition of angiotensin II type 1 receptor in the mechanically loaded heart.

Jian Wu1, Jieyun You, Shijun Wang, Li Zhang, Hui Gong, Yunzeng Zou.   

Abstract

In the heart, mechanical load is a crucial regulator of myocardial structure and function; however, mechanical overload is a pathogenesis or comorbidity existing in a variety of heart diseases, such as hypertension, aortic regurgitation and myocardial infarction. Mechanical overload can be generally differentiated into 2 types, pressure overload (PO) and volume overload (VO), causing concentric and eccentric cardiac hypertrophy, respectively. The angiotensin II (AngII) type 1 receptor (AT1-R) is a 7 transmembrane G protein-coupled receptor that plays a critical role in load-induced cardiac hypertrophy. Early studies revealed the involvement of autocrine/paracrine mechanisms through stretch-induced release of AngII. Recent conceptually inspiring studies unraveled that the AT1-R could be also directly activated by mechanical stress. The activated AT1-R initiates intricate intracellular signaling pathways through G protein-dependent and G protein-independent mechanisms. AT1-R blocker (ARB) antagonizes the activation of AT1-R to regress cardiac remodeling. Some ARBs show properties of inverse agonism and arrestin-biased agonism at the AT1-R, which are potential therapeutic targets for the treatment of load-induced cardiac hypertrophy. This review summarizes the progress in the understanding of ligand- and mechanical stress-dependent activation of AT1-R, highlights recent data that investigate the role of AT1-R in the differentiation of PO- and VO-induced cardiac hypertrophy, and discusses the clinical relevance of inverse agonism and biased agonism of AT1-R ligands.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24813328     DOI: 10.1253/circj.cj-14-0470

Source DB:  PubMed          Journal:  Circ J        ISSN: 1346-9843            Impact factor:   2.993


  9 in total

1.  Cathepsins in heart disease-chewing on the heartache?

Authors:  Jordan Blondelle; Stephan Lange; Barry H Greenberg; Randy T Cowling
Journal:  Am J Physiol Heart Circ Physiol       Date:  2015-03-06       Impact factor: 4.733

Review 2.  Gender Differences in Cardiac Hypertrophy.

Authors:  Jian Wu; Fangjie Dai; Chang Li; Yunzeng Zou
Journal:  J Cardiovasc Transl Res       Date:  2019-08-15       Impact factor: 4.132

Review 3.  Cardiorenal syndrome: long road between kidney and heart.

Authors:  Carolina Victoria Cruz Junho; Mayra Trentin-Sonoda; Karine Panico; Raquel Silva Neres Dos Santos; Mariana Vieira Abrahão; Imara Caridad Stable Vernier; Cristina Ribas Fürstenau; Marcela Sorelli Carneiro-Ramos
Journal:  Heart Fail Rev       Date:  2022-02-08       Impact factor: 4.654

4.  Losartan counteracts the effects of cardiomyocyte swelling on glucose uptake and insulin receptor substrate-1 levels.

Authors:  Yamil Gerena; Janice Griselle Lozada; Bryan Jael Collazo; Jarold Méndez-Álvarez; Jennifer Méndez-Estrada; Walmor C De Mello
Journal:  Peptides       Date:  2017-09-07       Impact factor: 3.750

5.  Combined statin and angiotensin-converting enzyme (ACE) inhibitor treatment increases the lifespan of long-lived F1 male mice.

Authors:  Stephen R Spindler; Patricia L Mote; James M Flegal
Journal:  Age (Dordr)       Date:  2016-09-02

6.  Cyclic compressive loading activates angiotensin II type 1 receptor in articular chondrocytes and stimulates hypertrophic differentiation through a G-protein-dependent pathway.

Authors:  Fumihisa Nakamura; Ichiro Tsukamoto; Shinji Inoue; Kazuhiko Hashimoto; Masao Akagi
Journal:  FEBS Open Bio       Date:  2018-05-21       Impact factor: 2.693

7.  FKBP12.6 protects heart from AngII-induced hypertrophy through inhibiting Ca2+ /calmodulin-mediated signalling pathways in vivo and in vitro.

Authors:  Yun-Fei Xiao; Zhi-Xiong Zeng; Xiao-Hui Guan; Ling-Fang Wang; Chan-Juan Wang; Huidong Shi; Weinian Shou; Ke-Yu Deng; Hong-Bo Xin
Journal:  J Cell Mol Med       Date:  2018-04-22       Impact factor: 5.310

8.  Cardiac remodeling secondary to chronic volume overload is attenuated by a novel MMP9/2 blocking antibody.

Authors:  Lena Cohen; Irit Sagi; Einat Bigelman; Inna Solomonov; Anna Aloshin; Jeremy Ben-Shoshan; Zach Rozenbaum; Gad Keren; Michal Entin-Meer
Journal:  PLoS One       Date:  2020-04-09       Impact factor: 3.240

9.  Left ventricular response in the transition from hypertrophy to failure recapitulates distinct roles of Akt, β-arrestin-2, and CaMKII in mice with aortic regurgitation.

Authors:  Jian Wu; Jieyun You; Xiaoyan Wang; Shijun Wang; Jiayuan Huang; Qihai Xie; Baoyong Gong; Zhiwen Ding; Yong Ye; Cong Wang; Le Kang; Ran Xu; Yang Li; Ruizhen Chen; Aijun Sun; Xiangdong Yang; Hong Jiang; Fenghua Yang; Peter H Backx; Junbo Ge; Yunzeng Zou
Journal:  Ann Transl Med       Date:  2020-03
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.